HK Stock Market Move | GIANT BIOGENE (02367) rose more than 6% in intraday trading. GIANT BIOGENE expands its medical beauty matrix. Institutions indicate that market speculation risks are gradually being cleared.

GIANT BIOGENE (02367) rose more than 6% during trading hours, as of the time of this report, it has increased by 4.13% to HK$26.22, with a trading volume of HK$160 million. On the news front, GIANT BIOGENE's medical beauty matrix has recently expanded. In June, GIANT BIOGENE officially launched its 753 collagen needle, the first domestically produced recombinant type I collagen facial injection, entering the injection market dominated by type III collagen. In the same month, the company's self-developed cross-linked recombinant type III full-length collagen filling agent was approved by the NMPA, making it the world's first similar product used to improve neck wrinkles. Huachuang Securities released a research report stating that GIANT BIOGENE's medical beauty matrix has gradually taken shape, and the risk of cosmetics public opinion is gradually clearing, with the turning point beginning to emerge. Although medical beauty is still in the early stage of market education in the next year, with a relatively low contribution to performance, the potential is promising. Taking into account the suppression of Hong Kong stocks' consumer sentiment valuation, considering the overall situation, a PE ratio of 15x for the cosmetics business in 2026 is given, resulting in a market value of HK$29 billion; plus an additional potential medical beauty market value of HK$6 billion, the total target market value is HK$35 billion.